# FDA recall D-1069-2022

> **Mckesson Medical-Surgical Inc. Corporate Office** · Class II · drug recall initiated 2022-04-13.

## Product

Medroxyprogesterone acetate injectable suspension, USP, 150 mg/mL, 1 mL vials, packaged in a) single dose vial (NDC 0703-6801-01), b) 25-count box single dose vials (NDC 0703-6801-04), Rx only, MFG: Teva Pharma USA

## Reason for recall

cGMP deviations: Temperature abuse

## Distribution

USA nationwide.

## Key facts

- **Recall number:** D-1069-2022
- **Recalling firm:** Mckesson Medical-Surgical Inc. Corporate Office
- **Classification:** Class II
- **Product type:** drug
- **Status:** Terminated
- **Initiation date:** 2022-04-13
- **Report date:** 2022-06-15
- **Termination date:** 2023-11-30

- **Voluntary/Mandated:** Voluntary: Firm initiated
- **Location:** Richmond, VA, United States

## Primary source

FDA Enforcement Reports: https://www.accessdata.fda.gov/scripts/ires/index.cfm?Product=D-1069-2022

## Citation

> AI Analytics. FDA recall D-1069-2022. Retrieved 2026-06-01 from https://api.ai-analytics.org/recall/D-1069-2022. Source: US FDA. Licensed CC0.

---

*[Dataset catalog](/datasets/) · [FDA recalls dataset](/datasets/fda-recalls) · CC0 1.0*